Role of quality control pathways in human diseases involving protein misfolding

被引:92
作者
Welch, WJ
机构
[1] Univ Calif San Francisco, Surg Res Lab, Dept Surg, San Francisco, CA 94110 USA
[2] Univ Calif San Francisco, Surg Res Lab, Dept Physiol, San Francisco, CA 94110 USA
[3] Univ Calif San Francisco, Surg Res Lab, Dept Med, San Francisco, CA 94110 USA
关键词
protein folding; human disease; molecular; chemical and pharmacological chaperones;
D O I
10.1016/j.semcdb.2003.12.011
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Advances in connecting phenotype to genotype have led to new insights regarding the basis of human disease. Many inherited diseases are now known to arise due to specific mutations within a gene that then lead to a protein product unable to assume a stable conformation within the cell. Cellular machineries serving as "quality control monitors" recognize and target such abnormally folded proteins for rapid destruction. As a consequence, specific biochemical pathways requiring the protein of interest are adversely affected and lead to the disease phenotype. Yet in other cases, upon its misfolding the particular protein quickly aggregates, leading to the formation of inclusion bodies that eventually lead to cell demise. In what follows I discuss some classic examples of human diseases known to arise due to mutations that lead to altered protein folding, abnormal protein maturation and/or protein aggregation. In many cases simply altering the protein folding environment within the cell, via molecular or pharmacological approaches, can effectively rescue the maturation and stability of the mutant protein and thereby reduce the onset and/or progression of the disease phenotype. These new insights regarding the mechanisms underlying the disease phenotype, as well as new approaches to correct the protein folding defect, will undoubtedly prove to have a tremendous impact on clinical medicine. (C) 2003 Elsevier Ltd. All rights reserved.
引用
收藏
页码:31 / 38
页数:8
相关论文
共 69 条
[1]  
Adachi H, 2003, J NEUROSCI, V23, P2203
[2]   Chaperone suppression of α-synuclein toxicity in a Drosophila model for Parkinson's disease [J].
Auluck, PK ;
Chan, HYE ;
Trojanowski, JQ ;
Lee, VMY ;
Bonini, NM .
SCIENCE, 2002, 295 (5556) :865-868
[3]   Correcting temperature-sensitive protein folding defects [J].
Brown, CR ;
HongBrown, LQ ;
Welch, WJ .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (06) :1432-1444
[4]  
Brown CR, 1996, CELL STRESS CHAPERON, V1, P117, DOI 10.1379/1466-1268(1996)001<0117:CCCTMP>2.3.CO
[5]  
2
[6]   MOLECULAR-BASIS OF OSMOTIC REGULATION [J].
BURG, MB .
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL FLUID AND ELECTROLYTE PHYSIOLOGY, 1995, 268 (06) :F983-F996
[7]   Chemical chaperones mediate increased secretion of mutant α1-antitrypsin (α1-AT) Z:: A potential pharmacological strategy for prevention of liver injury and emphysema in α1-AT deficiency [J].
Burrows, JAJ ;
Willis, LK ;
Perlmutter, DH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (04) :1796-1801
[8]   SULFATED POLYANION INHIBITION OF SCRAPIE-ASSOCIATED PRP ACCUMULATION IN CULTURED-CELLS [J].
CAUGHEY, B ;
RAYMOND, GJ .
JOURNAL OF VIROLOGY, 1993, 67 (02) :643-650
[9]  
Chai YH, 1999, J NEUROSCI, V19, P10338
[10]   Genetic modulation of polyglutamine toxicity by protein conjugation pathways in Drosophila [J].
Chan, HYE ;
Warrick, JM ;
Andriola, I ;
Merry, D ;
Bonini, NM .
HUMAN MOLECULAR GENETICS, 2002, 11 (23) :2895-2904